E. Calarco
8 Papers
E. Calarco is an academic researcher. The author has contributed to research in topics: Biology & Neuroblastoma. The author has an hindex of 2, co-authored 6 publications.
Chat about Author
Papers
Recent advances in the developmental origin of neuroblastoma: an overview
Mirco Ponzoni,Tiziana Bachetti,Maria Valeria Corrias,Chiara Brignole,Fabio Pastorino,E. Calarco,Veronica Bensa,Elena Giusto,Isabella Ceccherini,Patrizia Perri +9 more
TL;DR: In this paper , a broad overview of the latest advances that have unraveled the developmental origin of NB and its complex epigenetic landscape is presented, including single-cell RNA sequencing with spatial transcriptomics and lineage tracing, revealing that adrenal NB cells transcriptionally resemble immature neuroblasts or their closest progenitors.
Recent advances in the developmental origin of neuroblastoma: an overview
Mirco Ponzoni,Tiziana Bachetti,Maria Valeria Corrias,Chiara Brignole,Fabio Pastorino,E. Calarco,Veronica Bensa,Elena Giusto,Isabella Ceccherini,Patrizia Perri +9 more
TL;DR: In this paper , a broad overview of the latest advances that have unraveled the developmental origin of NB and its complex epigenetic landscape is presented, including single-cell RNA sequencing with spatial transcriptomics and lineage tracing, revealing that adrenal NB cells transcriptionally resemble immature neuroblasts or their closest progenitors.
64
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
Chiara Brignole,E. Calarco,Veronica Bensa,Elena Giusto,Patrizia Perri,Eleonora Ciampi,Maria Valeria Corrias,Simonetta Astigiano,Michele Cilli,Derik Loo,Ezio Bonvini,Fabio Pastorino,Mirco Ponzoni +12 more
TL;DR: Vobra duo exerts relevant antitumor activity in preclinical B7-H3-expressing NB models and represents a potential candidate for clinical translation.
7
Nucleolin expression has prognostic value in neuroblastoma patients
Davide Cangelosi,Chiara Brignole,Veronica Bensa,Roberto Tamma,Fabiana Malaguti,Barbara Carlini,Elena Giusto,E. Calarco,Patrizia Perri,Domenico Ribatti,Nuno A. Fonseca,João Nuno Moreira,Alessandra Eva,Loredana Amoroso,Massimo Conte,Alberto Garaventa,Angela Rita Sementa,Maria Valeria Corrias,Mirco Ponzoni,Fabio Pastorino +19 more
TL;DR: In this paper , NCL protein expression was retrospectively evaluated in tumour samples of NB patients at diagnosis and after chemotherapy and compared by log-rank test in a cohort of 20 patients with stage 4 NB and 786 patients of all stages (validation dataset).
4
From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models
Mario Capasso,Chiara Brignole,Vito Alessandro Lasorsa,Veronica Bensa,Sueva Cantalupo,Enrico Sebastiani,Alessandro Quattrone,Eleonora Ciampi,Marianna Avitabile,Angela Rita Sementa,Katia Mazzocco,Barbara Cafferata,Gabriele Gaggero,Valerio G. Vellone,Michele Cilli,E. Calarco,Elena Giusto,Patrizia Perri,Sanja Aveic,Doriana Fruci,Annalisa Tondo,Roberto Luksch,R. Mura,Marco Rabusin,Francesco De Leonardis,Monica Cellini,Paola Coccia,Achille Iolascon,Maria Valeria Corrias,Massimo Conte,A. Garaventa,Loredana Amoroso,Mirco Ponzoni,Fabio Pastorino +33 more
TL;DR: PreME confirms the possibility of identifying targetable genomic alterations in NB, indeed, a molecular targeted therapy was applied to four NB patients and paves the way to the creation of clinically relevant repositories of faithful patient-derived and 3D models.